Popular terms

Factor Viii topics
Factor Viii
Nucleotide
Antibodies
Polynucleotide
Polypeptide
Sialic Acid
Circulatory
Recombinant
Ethylene Glycol
Coagulation
Hemophilia
Physiologic
Endogenous
Prophylaxis
Blood Coagulation

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Factor Viii patents



      

This page is updated frequently with new Factor Viii-related patent applications.




Date/App# patent app List of recent Factor Viii-related patents
07/14/16
20160200795 
 Factor viii: remodeling and glycoconjugation of factor viii patent thumbnailFactor viii: remodeling and glycoconjugation of factor viii
The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.. .
Novo Nordisk A/s


07/14/16
20160200794 
 Complex patent thumbnailComplex
The present invention relates to a covalent complex of von willebrand factor (vwf) and factor viii, wherein the complex is modified such that it has an extended half-life in vivo. The invention further relates to a method of producing the complex, as well as the therapeutic or prophylactic use of the complex for treating or preventing bleeding events..
Csl Limited


07/14/16
20160199501 
 Factor viii zwitterionic polymer conjugates patent thumbnailFactor viii zwitterionic polymer conjugates
The present invention provides multi-armed high mw polymers containing hydrophilic groups conjugated to factor viii, and methods of preparing such polymers.. .
Kodiak Sciences Inc.


07/14/16
20160199455 
 Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof patent thumbnailFactor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
The present invention provides methods of administering factor viii; methods of administering chimeric and hybrid polypeptides comprising factor viii; chimeric and hybrid polypeptides comprising factor viii; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.. .
Biogen Hemophilia Inc.


07/14/16
20160199454 
 Factor viii-xten fusions and uses thereof patent thumbnailFactor viii-xten fusions and uses thereof
The present invention provides chimeric proteins comprising a factor viii (fviii) polypeptide and xten polypeptides. The fviii polypeptide can have a reduced affinity for von willebrand factor (vwf).
Amunix Operating Inc.


07/07/16
20160193353 
 Factor viii: remodeling and glycoconjugation of factor viii patent thumbnailFactor viii: remodeling and glycoconjugation of factor viii
The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.. .
Novo Nordisk A/s


06/30/16
20160185817 
 Purification of chimeric fviii molecules patent thumbnailPurification of chimeric fviii molecules
The invention is directed to methods of purifying a chimeric protein comprising subjecting the chimeric protein to a factor viii-specific affinity chromatography, and subjecting the chimeric protein to an aex chromatography; wherein the chimeric protein comprises a factor viii protein or a fragment thereof. The chimeric protein purified by the present methods shows improved factor viii activity..

06/30/16
20160184403 
 Treatment of coagulation disease by administration of recombinant vwf patent thumbnailTreatment of coagulation disease by administration of recombinant vwf
The present invention provides methods of treating coagulation disease, including hemophilia and von willebrand disease by administering recombinant von willebrand factor alone or in combination with factor viii.. .

06/23/16
20160175402 
 Polymer-factor viii moiety conjugates patent thumbnailPolymer-factor viii moiety conjugates
Conjugates of a factor viii moiety and one or more water-soluble polymers are provided. Typically, the water-soluble polymer is poly(ethylene glycol) or a derivative thereof.

05/19/16
20160136291 
 Polymers for delivery of factor viii and/or factor ix patent thumbnailPolymers for delivery of factor viii and/or factor ix
In some aspects, a composition comprising a ph-sensitive crosslinked copolymer of methacrylic acid and poly(ethylene glycol) monomethyl ether methacrylate and a therapeutic protein is provided. In some embodiments, the therapeutic protein is a high molecular weight protein such as factor viii or factor ix.
Board Of Regents, The University Of Texas System


05/12/16
20160130361 

Anti-factor viii antibodies or uses thereof


The present invention provides anti-fviii antibodies and antigen-binding molecules thereof which specifically bind fviii epitopes. The antibodies and antigen-binding molecules can be used to purify fviii.
Biogen Ma Inc.


05/05/16
20160120953 

Factor viii conjugates


The present invention relates to fviii conjugated to heparosan (hep) polymers, methods for the manufacture thereof and uses of such conjugates. The resultant conjugates may be used in the treatment or prevention of bleeding disorders such as haemophilia..
Novo Nordisk A/s


04/28/16
20160115219 

Factor viii glycoforms


The invention concerns glycosylated proteins having human factor viii activity. In a preferred embodiment, the protein is glycosylated with oligosaccharides that include an alpha-(2,6)-linked sialic acid and a bisecting glcnac linked to a core beta-mannose..
Bayer Healthcare Llc


04/14/16
20160102133 

Mutant factor viii compositions and methods


In one aspect, present invention provides a recombinant mutant human factor viii having increased expression and/or secretion as compared to wild-type factor viii. In certain embodiments, the recombinant factor viii includes one or more amino acid substitution(s) selected from the group consisting of i86, y105, a108, d115, q117, f129, g132, h134, m147 and l152.

03/10/16
20160067674 

Ligands and methods for isolating or removing proteins


The present disclosure relates generally to sorbents for binding proteins from blood plasma comprising a solid carrier material and an oligopeptide immobilized thereon, which selectively binds the protein from the blood plasma, and to a method for separating autologous proteins from blood plasma wherein the blood plasma is brought in contact with a corresponding sorbent, the desired protein is allowed to bind to the sorbent, the sorbent is separated from the plasma and the protein is subsequently separated from the sorbent. Corresponding sorbents and method allows for the selective isolation of specific blood plasma proteins directly from the blood plasma without having to conduct a tedious fractionation.
Previpharma Ag


03/03/16
20160060324 

Methods and compositions for treating bleeding disorders


The present invention provides immune conjugates for inducing antigen specific immune tolerance to coagulation factor viii. The immune conjugates contain a fviii protein or antigenic fragment that is conjugated to a binding moiety for a sialic acid binding ig-like lectin (siglec) expressed on b cells.
The Scripps Research Institute


03/03/16
20160058842 

Factor viii polymer conjugates


The invention is a proteinaceous construct comprising a factor viii molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of factor viii, and methods of preparing same.. .
Baxalta Gmbh


02/25/16
20160051633 

Methods of treating hemophilia in patients having developed inhibitory antibodies


This invention relates to factor viii muteins that are covalently bound, at a predefined site that is not an n-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain fviii procoagulant activity and have improved pharmacokinetic properties..
Bayer Healthcare Llc


02/18/16
20160045575 

Factor viii mutation repair and tolerance induction and related cdnas, compositions, methods and systems


The present disclosure relates to methods, systems, and compositions to repair one or more mutations in a factor viii gene sequence of a subject by introducing into a cell of the subject one or more polynucleotides encoding a dna scission enzyme (dna-se) and one or more repair vehicles (rvs) containing at least a cdna-repair sequence (rs) such that insertion of the cdna-rs through homologous recombination with the f8 gene of the subject (sf8) provides a repaired f8 gene (rf8), the repaired f8 gene (rf8) upon expression forming a functional fviii conferring improved coagulation functionality to the fviii protein encoded by the sf8. The present disclosure also relates to cells derived using the methods, systems and compositions described..

02/11/16
20160038575 

Compositions and methods for immune tolerance induction to factor viii replacement therapies in subjects with hemophilia a


This disclosure relates to tolerance inducing peptide (tip) derived from the amino acid reference locus (aarl) within a fviii replacement product (fviiirp) based on the differences between the expression product of a subject's f8 gene (sfviii) and the fviiirp to provide tolerance induction before, during, and/or after a fviii replacement therapy in a subject suffering from hemophila a. Methods of deriving, making, and using the tip are also disclosed.
Department Of Veterans Affairs


02/04/16
20160031968 

Variant factor viii polypeptides and methods of their production and use


This disclosure relates to variant factor viii polypeptides comprising an amino acid substitution at one or more positions within one or both of the thrombin cleavage site and the activation loop. In certain embodiments, the variant factor viii polypeptide comprises one or more amino acid substitutions within both the thrombin cleavage site and the activation loop.
Bayer Healthcare Llc


02/04/16
20160030529 

Targeted elimination of factor viii immune cells


This disclosure relates to composition and methods for improving blood clotting in a subject that developed anti-factor viii antibodies. In certain embodiments, this disclosure contemplates a conjugate comprising a toxin, e.g., ricin, abrin, saporin, coupled to factor viii or functional variant thereof either through a linking group or as a fusion protein..
Emory University


02/04/16
20160030524 

Recombinant factor viii formulations


Provided are liquid and lyophilized recombinant factor viii formulations, including formulations for polymer-conjugated fviii such as pegylated factor viii.. .
Bayer Healthcare Llc


01/07/16
20160003850 

Methods and compositions for diagnosis and prognosis of renal injury and renal failure


The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of coagulation factor x, coagulation factor v, soluble receptor tyrosine-protein kinase erbb-2, interferon beta, c-type lectin domain family 11 member a, glyceraldehyde-3-phosphate dehydrogenase, interferon omega-1, coagulation factor viii, thrombin-antithrombin-iii complex, and soluble tumor necrosis factor ligand superfamily member 13b as diagnostic and prognostic biomarkers in renal injuries..
Astute Medical, Inc.


01/07/16
20160002314 

Factor viii variants having a decreased cellular uptake


The present invention relates to modified coagulation factors. In particular, the present invention relates to modied factor viii molecules having decreased cellular uptake..
Sanquin Blood Supply Foundation


01/07/16
20160000884 

Liquid factor viii formulations


The invention is directed to a liquid, aqueous formulation of coagulation factor viii, comprising a factor viii molecule, a calcium salt in a concentration of more than 10 mm, and a saccharide and/or polyol in a concentration of at least 100 mm, wherein the formulation has a ph from 5.5-7.5. The invention furthermore provides a method for optimising a liquid formulation of coagulation factor viii, the method comprising the steps of: (i) providing one or more liquid formulations comprising factor viii to be tested; (ii) adding a protein denaturant to said liquid formulations, and incubating the resulting solutions for a predetermined period of time; (iii) analysing the incubated solutions of (ii) for the presence of dissociated factor viii; and (iv) selecting one or more formulation(s) having a desired low level of dissociated factor viii..
Novo Nordisk A/s


12/31/15
20150376612 

Ccctc-binding factor (ctcf) rna interactome


This invention relates to methods and compositions for selectively reactivating or downregulating certain genes, e.g., genes regulated by zinc-finger protein ccctc-binding factor (ctcf) on autosomes (e.g., imprinted genes, tumor suppressors, cancer) and the inactive x chromosome (xi), e.g., genes associated with x-linked diseases, e.g., rett syndrome, factor viii or ix deficiency, fragile x syndrome, duchenne muscular dystrophy, and pnh, in heterozygous females carrying a mutated allele, in addition to a functional wildtype or hypomorphic allele.. .
The General Hospital Corporation


12/31/15
20150376262 

Factor viii molecules with reduced vwf binding


The present invention relates to a recombinant factor viii molecule, wherein said molecule has reduced vwf binding capacity, and wherein said molecule is covalently conjugated with at least one side group.. .
Novo Nordisk A/s


12/24/15
20150366947 

A purifying therapeutic proteins


The present invention relates generally to a method of reducing the level of at least one protein selected from the group consisting of plasminogen, tissue plasminogen activator and other protease(s) in a solution comprising at least one protein selected from the group consisting of fibrinogen, factor viii and von willebrand factor (vwf), the method comprising: (i) passing a feedstock comprising at least one protein selected from the group consisting of fibrinogen, factor viii and vwf through a hydrophobic charge-induction chromatographic resin under conditions selected such that at least one protein selected from the group consisting of plasminogen, tissue plasminogen activator and other protease(s) present in the feedstock is bound to the resin; and (ii) recovering a solution comprising the at least one protein selected from the group consisting of fibrinogen, factor viii and vwf which passes through the resin, wherein the concentration of the at least one protein selected from the group consisting of plasminogen, tissue plasminogen activator and other protease(s) in the solution is reduced by at least 50% compared to the feedstock. Also provided are solutions and pharmaceutical formulations comprising the fibrinogen and/or factor viii and/or vwf recovered by such methods, and uses thereof..
Csl Behring Gmbh


12/17/15
20150361158 

Optimized factor viii gene


The present invention provides codon optimized factor viii sequences, vectors and host cells comprising codon optimized factor viii sequences, polypeptides encoded by codon optimized factor viii sequences, and methods of producing such polypeptides.. .
Biogen Ma Inc.


12/10/15
20150353625 

Variant of antihemophilic factor viii having increased specific activity


The present invention is in the field of hemophilia therapy. It relates to a new variant of antihemophilic factor viii having increased specific activity in comparison to known factor viii products..
Baxalta Gmbh


12/10/15
20150352190 

Modified factor viii


Methods of treating patients with factor viii deficiency by administration of modified porcine factor viii are disclosed. The particular modified porcine factor viii is one in which most of the b domain has been removed through genetic engineering.
Emory University


11/26/15
20150337028 

Double mutant coagulation factor viii and methods thereof


A double mutant b-domain deleted factor viii gene having mutations at phe309ser and asp519val, respectively, is disclosed for use in the field of haemophilia therapeutics. The disclosure a double mutant b-domain deleted factor viii protein having mutations at phe309ser and asp519val respectively, is also disclosed, as well as methods of producing the same.
Christian Medical College


11/05/15
20150315263 

Monolith-based pseudo-bioaffinity purification methods for factor viii and applications thereof


The present disclosure relates to purification of factor viii protein and/or its fragments from various sources by employing monolith based pseudobioaffinity purification methods. In particular, l-histidine over cim monolith [histidine ligand affinity chromatography (hlac)] is used for the purification of wild-type factor viii from plasma cryoprecipitate, recombinant b-domain deleted factor viii (rbdd-fviii) expressed in various host systems and recombinant factor viii light chain expressed in pichia pastoris.
Centre For Bioseparation Technology - Vit


10/29/15
20150306250 

Factor viii mutation repair and tolerance induction


Methods of treating hemophilia a in a subject with an f8 gene mutation, wherein the f8 gene is repaired and the resultant repaired gene, upon expression, confers improved coagulation functionality to the encoded fviii protein of the subject compared to the non-repaired f8 gene. The invention also includes methods of inducing immune tolerance to a fviii replacement product ((r)fviii) in a subject having a fviii deficiency, wherein the f8 gene mutation is repaired and the repaired gene, upon expression, provides for the induction of immune tolerance to an administered replacement fviii protein product.
The United States Government As Represented By The Deparment Of Veterans Affairs


10/29/15
20150306192 

Modified fviii apitope peptides


The present invention provides peptides partly derivable from fviii which are capable of binding to an mhc class ii molecule without further antigen processing and being recognised by a factor viii specific t cell. In particular, the present invention provides peptides comprising the sequence dnimvtfrnqasrpy or prcltryyssfvnme with modifications at the n- and c-termini.
Apitope International Nv


10/08/15
20150283267 

Vectors for liver-directed gene therapy of hemophilia and methods and use thereof


The present invention relates to vectors containing liver-specific regulatory sequences and codon-optimized factor ix or factor viii genes, methods employing these vectors and uses of these vectors. Expression cassettes and vectors containing these liver-specific regulatory elements and codon-optimized factor ix or factor viii genes are also disclosed.

10/01/15
20150273082 

Optimised coding sequence and promoter


An optimized coding sequence of human blood clotting factor eight (viii) and a promoter may be used in vectors, such as raav, for introduction of factor viii, and/or other blood clotting factors and transgenes. Exemplary of these factors and transgenes are alpha-1-antitrypsin, as well as those involved in the coagulation cascade, hepatocyte biology, lysosomal storage, urea cycle disorders, and lipid storage diseases.
St. Jude Children's Research Hospital


09/24/15
20150266944 

Methods of using fviii polypeptide


The present invention provides methods of reducing or decreasing the annualized bleeding rate of a human subject having hemophilia by administering a long acting factor viii polypeptide. The long-acting fviii polypeptide can be used for individual prophylaxis, weekly prophylaxis, episodic (on-demand) treatment, or perioperative management of hemophilia.
Biogen Idec Ma Inc.


09/24/15
20150266943 

Factor viii complex with xten and von willebrand factor protein, and uses thereof


The present invention includes a chimeric protein comprising a vwf protein with d′ domain and d3 domain of vwf, one or more xten sequence, and a fviii protein, wherein the vwf fragment, the xten sequence, or the fviii protein are linked to or associated with each other. The chimeric protein can further comprise one or more ig constant region or a portion thereof (e.g., an fc region).
Biogen Ma Inc.


08/27/15
20150240287 

Method for evaluating blood coagulation reaction


Various methods for evaluating hemostatic effect and various blood coagulation initiation reagents were studied to construct a method for evaluating blood coagulation reaction mediated by a substance having an activity of substituting for coagulation factor viii (fviii). As a result, it was discovered that by using a coagulation initiation reagent containing activated coagulation factor xi (fxia) and phospholipids, the effect of a substance having an activity of substituting for coagulation factor viii (fviii) on blood coagulation reaction can be evaluated using the amount of thrombin generated in the blood sample as an indicator..
Public University Corporation Nara Medical University


08/27/15
20150239984 

Therapeutic factor viii antibodies


The present invention relates to therapeutic fviii antibodies. In particular, the present invention relates to fviii antibodies having the ability to prolong the circulatory half life of fviii.
Novo Nordisk A/s


08/13/15
20150225717 

Selective reactivation of genes on the inactive x chromosome


Methods and compositions for selectively reactivating genes on the inactive x chromosome (xi) in a locus-specific manner, e.g., genes associated with x-linked diseases, e.g., rett syndrome, factor viii or ix deficiency, fragile x syndrome, duchenne muscular dystrophy, and pnh, in heterozygous females.. .
The General Hospital Corporation


08/13/15
20150225472 

Methods for producing recombinant factor viii chains from non-filamentous fungi, their functional reconstitution and applications thereof


A process of producing heavy chain peptide and/or light chain peptide of recombinant factor viii protein includes using the pichia pastoris expression system. A process of producing a functional recombinant factor viii protein by reconstituting the heavy chain and light chain produced using said pichia pastoris expression system.
Christian Medical College


08/13/15
20150224203 

Factor viii conjugates


The present invention relates to fviii conjugated to heparosan (hep) polymers, methods for the manufacture thereof and uses of such conjugates. The resultant conjugates may be used in the treatment or prevention of bleeding disorders such as haemophilia..
Novo Nordisk A/s


08/06/15
20150216944 

Allelic variants of human factor viii


Disclosed are compositions and methods related to factor viii.. .
Haplomics, Inc


07/30/15
20150210737 

Integrated process for the production of therapeutics (human albumin, intravenous immunoglobulins, clotting factor viii and clotting factor ix) from human plasma


The purification carried out by an all-chromatography scheme, avoids the use of ethanol precipitation in the entire manufacturing process of the said four plasma products. The invention describes an integrated process for purifying four different proteins from human plasma to high therapeutic grade purity levels, with a potential to purify more therapeutic proteins from a given plasma sample by incorporating additional chromatography steps in the sequence..



Factor Viii topics: Factor Viii, Nucleotide, Antibodies, Polynucleotide, Polypeptide, Sialic Acid, Circulatory, Recombinant, Ethylene Glycol, Coagulation, Hemophilia, Physiologic, Endogenous, Prophylaxis, Blood Coagulation

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Factor Viii for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Factor Viii with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.1818

4794

2 - 1 - 102